Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALASUR: Talazoparib and Avelumab Maintenance in Urothelial Carcinoma
NCT04678362Phase 2Recruiting
- Sponsor
- Centre François Baclesse
- Start
- Jun 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in urothelial carcinoma (UC), sponsored by Centre François Baclesse. Started Jun 2021; status: recruiting.
02
Drugs
talazoparib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04678362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678362.